Good morning, everyone, and how are you today? Another busy is unfolding here on the Pharmalot campus, where the shortest of short people has left for the local schoolhouse and the official mascots are taking their third nap of the day. Unfortunately, we are unable to join them, since our to-do list remains rather impressive. So instead, we are quaffing cups of stimulation and keeping busy. We trust that you relate. Meanwhile, here are a few items of interest to help you along. Hope you conquer the world today and do keep us in mind for intriguing developments …
More Indian drug makers are pursuing acquisitions, The Wall Street Journal writes. Last year, they reached deals valued at $1.5 billion to buy US firms, according to Dealogic. And since 2010, Indian pharmaceutical companies acquired or agreed to acquire 31 US drug makers. “These are very ambitious moves to go to where the market is,” Dilip Shah, head of the Indian Pharmaceutical Alliance, a trade group, tells the paper.
US federal prosecutors alleged at a hearing that corrupt Chinese government officials offered financial support and may have benefited from a plan to steal trade secrets from a GlaxoSmithKline research facility in Pennsylvania, the Associated Press writes. But defense lawyers argued the feds are exaggerating and that a Chinese company formed by the former Glaxo scientists received standard economic grants.
About the Author Reprints
